Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparative cardiovascular safety of romosozumab versus bisphosphonates in Japanese patients with osteoporosis: a new-user, active comparator design with instrumental variable analyses.
J Bone Miner Res
January 2025
Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima Medical University, Fukushima-city, Fukushima, Japan.
This study analyzed the association of romosozumab, a human monoclonal antibody with bone-forming and bone resorption-inhibiting effects, and bisphosphonates with the development of cardiovascular disease among patients with osteoporosis. A new-user design was employed to address selection bias, and instrumental variable analysis was used to address confounding by indication. Japanese patients aged ≥40 years, diagnosed with osteoporosis or experienced a fragility fracture, were admitted to medical facilities covered by a commercial administrative claims database, and newly prescribed romosozumab or bisphosphonates after the commercialization of romosozumab in Japan (March 4, 2019) were included based on verification of a 180-day washout period.
View Article and Find Full Text PDFImprovement of bone properties in children with osteogenesis imperfecta after pamidronate: a bone biopsy study.
JBMR Plus
February 2025
INSERM UMR 1033, Univ Lyon, Université Claude Bernard Lyon 1, F-69008 Lyon, France.
OI, or bone brittle disease, is characterized by increased mineralization of bone matrix independently of clinical severity. So, a beneficial effect of antiresorptive treatments such as bisphosphonates (BP) is questionable. We aim to compare the bone matrix characteristics before and after BP pamidronate (PAM).
View Article and Find Full Text PDFImpact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.
Osteoporos Int
January 2025
Kobayakawa Orthopaedics and Rheumatologic Clinic, 1969 Kuno, Fukuroi, Shizuoka, 437-0061, Japan.
Unlabelled: This case-control study investigated the impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in postmenopausal osteoporosis. Romosozumab demonstrated the most significant improvements in bone mineral density, particularly in the lumbar spine and total hip, by reducing bone resorption and increasing bone formation markers.
Purpose: To investigate the impact of switching from bisphosphonates (BP) to denosumab (DMAb), teriparatide (TPTD), or romosozumab (ROMO) in postmenopausal osteoporosis.
The Development of Immobilization Induced Hypercalcemia in the Outpatient Setting - A Case Report.
S D Med
October 2024
Monument Health Rapid City Clinic, Rapid City, South Dakota.
Immobilization induced hypercalcemia is an uncommon and serious disorder that requires a thorough evaluation to exclude more common causes of an elevated calcium. Although the pathogenesis is not clearly illuminated, immobilization results in an uncoupling between osteogenic and osteoclastic factors that maintain bone homeostasis. When calcemic bone resorption overwhelms urinary calcium excretion, blood hypercalcemia ensues.
View Article and Find Full Text PDFEffectiveness of a co-management program with internal medicine on hip fracture patients at a regional hospital in northwest Spain. Co-inter-Monf study.
Eur J Trauma Emerg Surg
January 2025
Internal Medicine Department, Hospital Público de Monforte, Rua Corredoira s/n, Monforte de Lemos, 27400, Lugo, Spain.
Background: Hip fractures represent a serious public health problem with a high burden of mortality, morbidity, and resource use. Co-management has proven to enhance the clinical outcomes of hip fracture patients hospitalized in various settings.
Aim: This study aims to evaluate whether the previously observed benefits of co-management can be achieved when such a program is implemented in a rural-based district hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!